Clinical Trial Update: A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C [Phase 3]

View source ↗

Summary

Phase 3 trial results for tenapanor in constipation-predominant irritable bowel syndrome (IBS-C) with a 12-week treatment and 4-week withdrawal period; results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation-predominant Irritable Bowel Syndrome

Drugs mentioned

• Tenapanor (tenapanor)

Snippet

Sponsor: Ardelyx | Conditions: Constipation Predominant Irritable Bowel Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2020-04-21